Logo
x

Search category

Subscribe Now

Samsung Bioepis

Samsung Bioepis Successfully Resolves Patent Disputes with Johnson & Johnson

Samsung Bioepis Successfully Resolves Patent Disputes with Johnson & Johnson

  • December 1, 2023
The US FDA Accepted to Review Samsung Bioepis & Organon’s sBLA for Hadlima (Biosimilar, adalimumab) to Treat Plaque Psoriasis

The US FDA Accepted to Review Samsung Bioepis & Organon’s sBLA for Hadlima (Biosimilar, adalimumab) to Treat Plaque Psoriasis

  • November 9, 2023
Samsung Bioepis Presents Post-hoc Analysis of P-III Clinical Trial for SB15, a Proposed Biosimilar to Eylea (Aflibercept) at EURETINA 2023

Samsung Bioepis Presents Post-hoc Analysis of P-III Clinical Trial for SB15, a Proposed Biosimilar to Eylea (Aflibercept) at EURET...

  • October 9, 2023
Insights+ Key Biosimilars Events of August 2023

Insights+ Key Biosimilars Events of August 2023

  • September 7, 2023
Samsung Bioepis and Organon Report Interchangeability Study Results of SB5 (biosimilar, adalimumab) for Chronic Plaque Psoriasis

Samsung Bioepis and Organon Report Interchangeability Study Results of SB5 (biosimilar, adalimumab) for Chronic Plaque Psoriasis

  • August 2, 2023
Samsung Bioepis Reports P-III Equivalence Study Results of SB11 (biosimilar, ranibizumab) for Neovascular Age-Related Macular Degeneration

Samsung Bioepis Reports P-III Equivalence Study Results of SB11 (biosimilar, ranibizumab) for Neovascular Age-Related Macular Dege...

  • July 4, 2023
Image

Incisive News in 3 Shots.

Contact Us

Our Information

Follow Us

Copyright © 2023 PharmaShots - All Rights Reserved.